6-(1-{2-[4-(1H-imidazol-1-yl)phenyl]imidazo[1,2-b][1,2,4]triazin-7-yl}cyclopropyl)-quinoline | 1029713-72-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 6-(1-{2-[4-(1H-imidazol-1-yl)phenyl]imidazo[1,2-b][1,2,4]triazin-7-yl}cyclopropyl)-quinoline
• 英文别名: 6-[1-[2-(4-imidazol-1-ylphenyl)imidazo[1,2-b][1,2,4]triazin-7-yl]cyclopropyl]quinoline
• CAS: 1029713-72-1
• 化学式: C₂₆H₁₉N₇
• 分子量: 429.484
• InChiKey: MLXFBSKHEQEPPV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  33
• 可旋转键数：
  4
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  73.8
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  咪唑 、 6-{1-[2-(4-bromophenyl)imidazo[1,2-b][1,2,4]triazin-7-yl]cyclopropyl}quinoline 在 copper(l) iodide 、 (1S,2S)-(+)-N,N'-二甲基环己烷-1,2-二胺 potassium carbonate 作用下， 以 1,4-二氧六环 为溶剂， 生成 6-(1-{2-[4-(1H-imidazol-1-yl)phenyl]imidazo[1,2-b][1,2,4]triazin-7-yl}cyclopropyl)-quinoline
  参考文献：
  名称：

  WO2008/64157

  摘要：

  公开号：

文献信息

• IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS
  申请人：Incyte Holdings Corporation

  公开号：US20160326178A1

  公开（公告）日：2016-11-10

  The present invention is directed to imidazo[1,2-b][1,2,4]triazines and imidazo[1,2-a]pyrimidines, and pharmaceutical compositions thereof, which are inhibitors of kinases such as c-Met and are useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways.

  本发明涉及咪唑[1,2-b][1,2,4]三嗪和咪唑[1,2-a]嘧啶，以及其制成的药物组合物，该组合物是c-Met激酶抑制剂，可用于治疗癌症和与激酶通路失调有关的其他疾病。
• Imidazotriazines and imidazopyrimidines as kinase inhibitors
  申请人：Incyte Corporation

  公开号：EP2497470A1

  公开（公告）日：2012-09-12

  The present invention is directed to imidazo[1,2-b][1,2,4]triazines and imidazo[1,2-a]pyrimidines, and pharmaceutical compositions thereof, which are inhibitors of kinases such as c-Met and are useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways.

  本发明涉及咪唑并[1,2-b][1,2,4]三嗪和咪唑并[1,2-a]嘧啶及其药物组合物，它们是激酶（如 c-Met）的抑制剂，可用于治疗癌症和其他与激酶通路失调有关的疾病。
• Imidazotriaines and imidazopyrimidines as kinase inhibitors
  申请人：Incyte Corporation

  公开号：US10738052B2

  公开（公告）日：2020-08-11

  The present invention is directed to imidazo[1,2-b][1,2,4]triazines and imidazo[1,2-a]pyrimidines, and pharmaceutical compositions thereof, which are inhibitors of kinases such as c-Met and are useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways.

  本发明涉及咪唑并[1,2-b][1,2,4]三嗪和咪唑并[1,2-a]嘧啶及其药物组合物，它们是激酶（如 c-Met）的抑制剂，可用于治疗癌症和其他与激酶通路失调有关的疾病。
• COMBINATION THERAPIES
  申请人：Novartis AG

  公开号：EP3710053A1

  公开（公告）日：2020-09-23
• Imidazotriaines and Imidazopyrimidines as Kinase Inhibitors
  申请人：Incyte Corporation

  公开号：US20180282340A1

  公开（公告）日：2018-10-04

  The present invention is directed to imidazo[1,2-b][1,2,4]triazines and imidazo[1,2-a]pyrimidines, and pharmaceutical compositions thereof, which are inhibitors of kinases such as c-Met and are useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways.